Lv68
3110 积分 2024-06-18 加入
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
11天前
已完结
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
12天前
已完结
Discovery solubility measurement and assessment of small molecules with drug development in mind
17天前
已完结
Covalent inhibitors of the GTPase KRASG12C: a review of the patent literature
20天前
已完结
Evaluation of Oral PROTAC Guidelines: Efflux Ratio Outweighs Chameleonicity Descriptors
23天前
已完结
New Multiparameter Index Is a Strong Predictor of Oral Bioavailability for Heterobifunctional Degraders
23天前
已完结
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical Validation
26天前
已完结
Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025
1个月前
已完结
The European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Best Practice Initiative: Hit to Lead
1个月前
已完结
Biologic degraders push forward in the clinic
1个月前
已完结
皖公网安备34019202002308
